Atossa Therapeutics Appoints New CFO to Boost Financial Leadership and Commercialization Efforts

Atossa Therapeutics Strengthens Financial Leadership with New CFO Appointment

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to advancing breast cancer treatment and prevention, announces the appointment of Mark Daniel as Chief Financial Officer. This strategic move occurs as Atossa prepares to transition into commercial operations with its lead product, (Z)-endoxifen. With over 25 years of experience in life sciences finance, Daniel brings a robust background in revenue forecasting, public company controls, and capital markets that is essential for Atossa's growth strategy. His past experience includes managing significant operating budgets and implementing Sarbanes-Oxley (SOX) controls, which have yielded substantial cost savings.

The appointment of Mr. Daniel is pivotal for Atossa as it gears up for commercialization. Steven Quay, the company's Chairman and CEO, underscores the critical nature of Daniel's experience in developing revenue-ready systems and ensuring disciplined financial practices. As Atossa seeks to enhance its operational readiness, Daniel's focus will be on financial planning and aligning capital expenditures with value-creating milestones. This alignment is particularly important as the company aims to improve its revenue forecasting accuracy and implement a balanced capital strategy that supports a successful market entry.

Key initiatives under Daniel's leadership include a weekly revenue forecasting partnership with global sales teams to refine accuracy from bookings to cash. This systematic approach not only aims to bolster financial discipline at scale but also ensures compliance that has already led to a significant reduction in SOX-related expenditures. Overall, his extensive expertise is expected to fortify Atossa's financial framework and support the company's ambitious growth trajectory as it addresses unmet needs in breast cancer treatment.

In addition to its internal developments, Atossa Therapeutics is actively engaging with investors during the upcoming Maxim Growth Summit on October 22–23, 2025, at the Hard Rock Hotel in New York City. CEO Steven Quay will present at the event and is available for one-on-one meetings with potential investors, emphasizing the company's commitment to disciplined capital allocation and its focus on programs that could lead to regulatory submissions.

Atossa is also dedicated to keeping its investors informed. The company encourages stakeholders to explore its latest presentations, SEC filings, and FAQs available on its website, as well as to sign up for email alerts for ongoing updates. With a clear strategic focus and enhanced financial leadership, Atossa Therapeutics positions itself to address critical needs in breast cancer care effectively.